Monroe facility FDA observations unresolved
Five observations from last FDA inspection remain unresolved; management is awaiting FDA response. This could delay injectable product launches and revenue.
high · analyst_question
Glenmark Pharmaceuticals Limited — Q1 FY26
Glenmark's Q1 FY26 consolidated revenue was flat at ₹3,264 crore (+0.6% YoY), with India formulation growing 3.7% (secondary sales +15.1%) and North America up 8.9% QoQ to $91 m...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US antitrust litigation ongoing
Glenmark USA is still defending against multiple antitrust lawsuits; settlement with direct purchaser class is subject to court approval, and other classes remain.
medium · management_commentaryIndia business drag from diabetes segment and tail brand discontinuation
Reported India growth lagged secondary sales due to discontinuation of low-margin brands and diabetes underperformance; recovery expected only from Q3.
medium · management_commentaryISB 2001 deal closing delay or unfavorable terms
The AbbVie partnership is expected to close in September; any delay or renegotiation could impact cash position and IGI funding.
medium · analyst_question